Abstract 64P
Background
Tumor associated macrophages (TAMs) are highly abundant immune cells present within the microenvironment of multiple tumor types. TAMs with a type 2 (M2)-like phenotype generally associate with poor prognosis and resistance against immunotherapy. In fact, we observed high frequencies of M2-like TAMs relative to those of CD8+ T cells according to gene expression analyses in multiple tumor types. In this study, we aim to engineer CD8+ T cells that resist M2-like macrophage-mediated suppression.
Methods
First, we have set up an in vitro co-culture model of human autologous M2-like macrophages and CD8+ T cells that yields T cell suppression. To this end, we have polarized in vitro monocytes from healthy donors into M2-like macrophages using a cytokine cocktail, after which we have optimized critical parameters, such as type of T cell stimulation, co-culture duration and the ratio between the two cell types.
Results
With this model, we have demonstrated that M2-like macrophages from multiple donors, when co-cultured with anti-CD3/CD28 antibody-stimulated autologous CD8+ T cells for 6 days, suppressed T cell proliferation by 50%. In a second step, we have adapted this model to a CRISPR-Cas9 gene editing-based approach: single guide RNA lentiviral infection with Cas9 electroporation (SLICE). We have successfully performed single gene editing, and are currently editing CD8+ T cells with gene libraries targeting kinases.
Conclusions
Taken together, we present a robust in vitro model of M2-like macrophage-mediated suppression of CD8+ T cells which enables the identification of genes that contribute to suppression-resistant CD8+ T cells. The making of such synthetic T cells is anticipated to aid the anti-tumor efficacy of adoptive T cell therapy.
Legal entity responsible for the study
Erasmus MC.
Funding
KWF Kankerbestrijding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract